First-in-class CD39 checkpoint inhibitor presented at the AACR meeting
New data presented at AACR support the rationale for combination treatment with monalizumab and durvalumab
Innate Pharma presents new CD73 checkpoint inhibitor program
New preclinical data further supporting the development of IPH4301 presented at the AACR meeting
AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology
Sixth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification
Start of Phase I clinical trial of monalizumab in combination with durvalumab
Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology
Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
Fourth clinical trial opened with monalizumab (IPH2201)
